- Vince Holding Corp VNCE shares dipped 25 percent to $0.975. Vince reported a delay in fiscal 2016 10-K filing.
- Skyline Corporation SKY shares tumbled 23.8 percent to $6.44. Skyline posted a Q3 net loss of $2,447,000, or $0.29 per share, versus year-ago net loss of $520,000 or $0.06 per share.
- Oncomed Pharmaceuticals Inc OMED shares dropped 18.7 percent to $3.88 as the company disclosed that its Phase 2 trial of tarextumab did not meet endpoints. OncoMed also reported that it will discontinue enrollment in Phase 1B clinical trial of brontictuzumab.
- Snyder's-Lance Inc LNCE shares fell 18.5 percent to $32.55. Snyder's-Lance announced the retirement of its CEO and issued a weak forecast.
- Immune Pharmaceuticals Inc IMNP shares dropped 11.8 percent to $2.25 after declining 2.67 percent on Thursday.
- Apricus Biosciences Inc APRI shares dropped 11.3 percent to $1.72. Apricus Biosciences filed for offering of up to $6 million of units.
- China Auto Logistics Inc CALI shares fell 11.1 percent to $2.66.
- Incyte Corporation INCY dropped 11 percent to $125.34. The FDA on Friday declined to approve Eli Lilly and Co and Incyte arthritis drug Olumiant. PiperJaffray downgraded Incyte from Overweight to Neutral.
- Timkensteel Corp TMST declined 10.9 percent to $15.77. TimkenSteel projects Q1 net sales of around $309 million on 280,000 ship tons and a net loss of around $5 million.
- Biostar Pharmaceuticals Inc BSPM shares dropped 10.8 percent to $2.03. Biostar Pharmaceuticals reported a FY16 net loss of $5.7 million on sales of $2.4 million.
- Adeptus Health Inc ADPT shares declined 9.8 percent to $2.11.
- Akari Therapeutics PLC (ADR) AKTX fell 9.6 percent to $14.48. Chardan Capital reiterated Akari Therapeutics with a Sell and raised the price target from $5.00 to $6.50.
- GWG Holdings Inc GWGH shares declined 9 percent to $9.60 after dropping 5.62 percent on Thursday.
- SemiLEDs Corporation LEDS shares dropped 8.6 percent to $2.87.
- Eli Lilly and Co LLY fell 4.1 percent to $82.39. The FDA on Friday declined to approve Eli Lilly and Incyte arthritis drug Olumiant. BMO Capital downgraded Eli Lilly from Market Perform to Underperform.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
